drugset / Trial / NCT00825487
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open-label, dose escalation study of intravenous ARQ 621 administered to patients with late-stage solid tumors or hematologic malignancies.
Timeline
- Start
- 2009-08
- Primary completion
- 2011-05
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ARQ 621 | Small molecule | 10 mg/m2 | Intravenous |
| Subject | ARQ 621 | Small molecule | 200 mg/m2 | Intravenous |